产品展示
AZD8931
点击次数：325发布时间：2013/4/2 15:47:33
更新日期：2022/8/19 17:45:40
所 在 地：美洲
产品型号：
优质供应
详细内容
AZD8931
上海义森生物科技有限公司
技术数据:
分子量（MW）: 473.93 
化学式: C23H25ClFN5O3
溶解度: DMSO 40mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 848942-61-0, 1196531-39-1 （diFumaric acid）
生物活性
AZD8931 is a novel potent reversible small molecule epidermal growth factor receptor, ERBB2 （HER2） ａnd ERBB3 inhibitor with an IC50 of 4, 3, 4 nM, respectively. In proliferation assays, AZD8931 was significantly more potent than gefitinib or lapatinib in specific squamous cell carcinoma of the head ａnd neck ａnd non-small cell lung carcinoma cell lines. In vivo, AZD8931 inhibited xenograft growth in a range of models while significantly affecting EGFR, erbB2, ａnd erbB3 phosphorylation ａnd downstream signaling pathways, apoptosis, ａnd proliferation. It has a unique pharmacologic profile providing equipotent inhibition of EGFR, erbB2, ａnd erbB3 signaling ａnd showing greater antitumor activity than agents with a narrower spectrum of erbB receptor inhibition in specific preclinical models. [1][2][3]
技术数据:
分子量（MW）: 473.93 化学式: C23H25ClFN5O3
溶解度: DMSO 40mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 848942-61-0, 1196531-39-1 （diFumaric acid）
生物活性
AZD8931 is a novel potent reversible small molecule epidermal growth factor receptor, ERBB2 （HER2） ａnd ERBB3 inhibitor with an IC50 of 4, 3, 4 nM, respectively. In proliferation assays, AZD8931 was significantly more potent than gefitinib or lapatinib in specific squamous cell carcinoma of the head ａnd neck ａnd non-small cell lung carcinoma cell lines. In vivo, AZD8931 inhibited xenograft growth in a range of models while significantly affecting EGFR, erbB2, ａnd erbB3 phosphorylation ａnd downstream signaling pathways, apoptosis, ａnd proliferation. It has a unique pharmacologic profile providing equipotent inhibition of EGFR, erbB2, ａnd erbB3 signaling ａnd showing greater antitumor activity than agents with a narrower spectrum of erbB receptor inhibition in specific preclinical models. [1][2][3]
技术数据:
分子量（MW）: 473.93 化学式: C23H25ClFN5O3
溶解度: DMSO 40mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 848942-61-0, 1196531-39-1 （diFumaric acid）
生物活性
AZD8931 is a novel potent reversible small molecule epidermal growth factor receptor, ERBB2 （HER2） ａnd ERBB3 inhibitor with an IC50 of 4, 3, 4 nM, respectively. In proliferation assays, AZD8931 was significantly more potent than gefitinib or lapatinib in specific squamous cell carcinoma of the head ａnd neck ａnd non-small cell lung carcinoma cell lines. In vivo, AZD8931 inhibited xenograft growth in a range of models while significantly affecting EGFR, erbB2, ａnd erbB3 phosphorylation ａnd downstream signaling pathways, apoptosis, ａnd proliferation. It has a unique pharmacologic profile providing equipotent inhibition of EGFR, erbB2, ａnd erbB3 signaling ａnd showing greater antitumor activity than agents with a narrower spectrum of erbB receptor inhibition in specific preclinical models. [1][2][3]
技术数据:
| 分子量（MW）: | 473.93 | |
|---|---|---|
| 化学式: | C23H25ClFN5O3 | |
| 溶解度: | DMSO 40mg/mL Water <1mg/mL Ethanol <1mg/mL | |
| 纯度: | >99% | |
| 稳定性: | at -20℃ 2 years | |
| CAS号: | 848942-61-0, 1196531-39-1 （diFumaric acid） |
生物活性
AZD8931 is a novel potent reversible small molecule epidermal growth factor receptor, ERBB2 （HER2） ａnd ERBB3 inhibitor with an IC50 of 4, 3, 4 nM, respectively. In proliferation assays, AZD8931 was significantly more potent than gefitinib or lapatinib in specific squamous cell carcinoma of the head ａnd neck ａnd non-small cell lung carcinoma cell lines. In vivo, AZD8931 inhibited xenograft growth in a range of models while significantly affecting EGFR, erbB2, ａnd erbB3 phosphorylation ａnd downstream signaling pathways, apoptosis, ａnd proliferation. It has a unique pharmacologic profile providing equipotent inhibition of EGFR, erbB2, ａnd erbB3 signaling ａnd showing greater antitumor activity than agents with a narrower spectrum of erbB receptor inhibition in specific preclinical models. [1][2][3]
